Opendata, web and dolomites

NO-ESKAPE SIGNED

Addressing Antibiotic Resistance: New Strategies for Overcoming the ESKAPE Pathogens

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NO-ESKAPE project word cloud

Explore the words cloud of the NO-ESKAPE project. It provides you a very rough idea of what is the project "NO-ESKAPE" about.

conventional    century    identification    head    eskape    critical    cell    bacteria    biosynthesis    rational    sequestering    aureus    health    modes    survival    almost    metallo    antibacterial    era    clear    enterobacter    gram    collection    negative    pursuit    grounded    mechanisms    antibiotics    worrisome    pneumoniae    pathogens    enzymes    resistant    beta    bacterial    describes    antibiotic    semi    faecium    discovery    outlined    microbial    innovation    strategies    inhibitors    post    world    delivering    innovative    wall    leads    diverse    baumanii    produces    natural    binding    drug    global    action    operate    resistance    suitable    responsible    screening    synthetic    alarming    positive    therapeutic    combination    pursued    tackle    escaping    species    poses    examined    entirely    organisms    prepared    21st    organic    prepare    valuable    lactamase    firmly    chemistry    interfering    unconventional    multidisciplinary    compounds    wealth    precursors    threat    combating    validate    aeruginosa   

Project "NO-ESKAPE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT UTRECHT 

Organization address
address: HEIDELBERGLAAN 8
city: UTRECHT
postcode: 3584 CS
website: www.uu.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://martinlab.nl
 Total cost 2˙000˙000 €
 EC max contribution 2˙000˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-COG
 Funding Scheme ERC-COG
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT UTRECHT NL (UTRECHT) coordinator 2˙000˙000.00

Map

 Project objective

Antibiotic resistance poses an alarming threat to global health. Most worrisome are the so-called “ESKAPE” pathogens (E. faecium, S. aureus, K. pneumoniae, A. baumanii, P. aeruginosa, and Enterobacter species), a collection of organisms capable of escaping the effects of almost all conventional antibiotics. Key to combating drug-resistant bacteria is the identification of new antibacterial targets and the ability to exploit these targets with novel and unconventional antibiotics.

The microbial world produces a wealth of antibacterial compounds that, while not suitable for therapeutic use, operate by diverse and unique modes of action. This proposal describes innovative approaches aimed at the discovery and development of such compounds as leads towards novel antibiotics with entirely new modes of action. Using a multidisciplinary approach, firmly grounded in synthetic organic chemistry, I will prepare and validate new antibiotics that target the ESKAPE pathogens by exploiting mechanisms critical to their survival and/or resistance.

To tackle the Gram-positive ESKAPE pathogens a number of new approaches to interfering with bacterial cell wall biosynthesis will be examined. Specifically, novel (semi)synthetic compounds capable of binding to and sequestering various bacterial cell wall precursors will be prepared and their antibiotic activity assessed. To address the Gram-negative ESKAPE pathogens, inhibitors of the metallo-beta-lactamase enzymes responsible for much of their antibiotic resistance will be pursued. These inhibitors will be achieved via a combination of rational design strategies and innovative natural product screening approaches.

The 21st century threat of a post-antibiotic era makes clear the need for innovation in antibacterial drug discovery. The strategies outlined in this proposal address this threat head-on with the aim of delivering valuable lead compounds in pursuit of novel antibiotics.

 Publications

year authors and title journal last update
List of publications.
2018 Kamaleddin H. M. E. Tehrani, Nathaniel I. Martin
β-lactam/β-lactamase inhibitor combinations: an update
published pages: 1439-1456, ISSN: 2040-2503, DOI: 10.1039/c8md00342d
MedChemComm 9/9 2019-12-16

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NO-ESKAPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NO-ESKAPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

OAlipotherapy (2018)

Long-retention liposomic drug-delivery for intra-articular osteoarthritis therapy

Read More  

QUAMAP (2019)

Quasiconformal Methods in Analysis and Applications

Read More  

CoolNanoDrop (2019)

Self-Emulsification Route to NanoEmulsions by Cooling of Industrially Relevant Compounds

Read More